PIRS (Pieris Pharmaceuticals) Forvard P/S multiplikatori
Pieris Pharmaceuticals (PIRS) uchun inqiroz boshqaruvi va kapitalning yashab qolishi uchun kurash bilan bog'liq xavflar mavjud. GURU.Markets platformasidagi ushbu grafik kutilayotgan daromad multiplikatorini aks ettiradi, bunda 821.20 ko'rsatkichi tayanch parametrining holatini belgilaydi. Barqarorlik protein testlari natijalariga asoslangan, o'sish potentsiali esa Anticalin platformasining rivojlanishi va biotexnologiya kompaniyalari bilan yangi sherikliklarga bog'liq.
Pieris Pharmaceuticals kompaniyasining tahliliy kesimlari
- bozor narxi va tahlilchilarning maqsadli narxlari:
- biznesning bozor baholash ko'rsatkichlari:
- emitentning balans qiymati statistikasi:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Umumiy qarzning kapitalga nisbati Pieris Pharmaceuticals|PIRS - Uzoq muddatli qarzdorlikning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Pieris Pharmaceuticals|PIRS - Kompaniyaning umumiy qarz majburiyatlari|Qarzning balans qiymatiga nisbati Pieris Pharma|PIRS - Kompaniyaning uzoq muddatli kredit va qarzlari|Kompaniyaning qisqa muddatli qarzi Pieris Pharmaceuticals|Tezkor likvidlik koeffitsiyenti pieris.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
PIRS - Yakuniy foyda|Prognoz qilingan kelajakdagi foyda Pieris Pharmaceuticals|PIRS - P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Pieris|PIRS - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati Pieris Pharma|PIRS - Eskirish chegirilmasdan oldingi operatsion foyda|Bir aksiya uchun sof foyda (EPS TTM) Pieris Pharmaceuticals|PIRS - Bir aksiya uchun sof foyda (EPS TTM)|Choraklik EPS foyda o'sishi pieris.com|PIRS - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Pieris Pharmaceuticals
- tushum va sotuvlar tafsilotlari:
Kompaniyaning har tomonlama tahlili:Pieris Pharmaceuticals, Inc. (PIRS)
Oldingi P/S koeffitsiyenti joriy bozor kapitalizatsiyasini prognoz qilingan savdo hajmi bilan solishtiradi, bu esa rasmiy moliyaviy hisobotlar e'lon qilinishidan oldin daromad o'sish sur'atlariga oid bozor kutuvlarini baholash imkonini beradi. Oldingi P/S tarixini tahlil qilish Pieris Pharmaceuticals (PIRS) kompaniyasining operatsion barqarorligini ochib beradi va investorlar dori vositalarini ishlab chiqishga akademik yondashuv kontekstida Anticalin proteinlarining tijoratlashtirish salohiyatini qanday baholashini namoyish etadi.
Muhim raqobatchilar
Narxning prognoz qilingan daromadga nisbati Haleon HLN|KVUE (Kenvue Inc) - Kelajakdagi narxning daromadga nisbati|Verona Pharma Corp - Forvard P/S multiplikatori|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Jyong Bio MENS|LGND: Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati amneal.com (AMRX)|Narxning prognoz qilingan daromadga nisbati Perrigo|ALVO: Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori LQDA|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Galapagos Corp|Narxning prognoz qilingan daromadga nisbati ANI Pharmaceuticals ANIP|Kapitalizatsiyaning kutilayotgan sotuvga nisbati mannkindcorp.com (MNKD)|AMPH: Forvard narx/daromad multiplikatori|Sotuvga nisbatan forvard narx PCRX (Pacira Pharmaceuticals)|ARS Pharma (SPRY) - Narxning prognoz qilingan daromadga nisbati|Kelajakdagi narxning daromadga nisbati TBPH (Theravance Corp)|AQST (Aquestive Therapeutics) - Forvard P/S multiplikatori|SCPH: Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori TECX|Forvard P/S multiplikatori Tonix Pharma (TNXP)|Narxning prognoz qilingan daromadga nisbati China SXT Pharmaceuticals, Inc. SXTC|Sotuvga nisbatan forvard narx EPRX|BHST - Narxning prognoz qilingan daromadga nisbati|invizyne.com (EXOZ) - Forvard narx/daromad multiplikatori|ORMP: Forvard P/S multiplikatori|Entera Bio (ENTX) - Forvard P/S multiplikatori|HYFT (MindWalk) - Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori ABVC BioPharma, Inc (ABVC)|Forvard P/S multiplikatori CPIX|QNTM - Bozor kapitallashuvining kelajakdagi daromadga nisbati|FibroGen - Forvard narx/daromad multiplikatori|Forvard P/S multiplikatori Telomir Pharmaceuticals Inc TELO|RANI: Forvard narx/daromad multiplikatori|Synergy CHC Corp - Narxning kutilayotgan daromadga nisbati|RLYB: Forvard P/S multiplikatori|LEXX - Kapitalizatsiyaning kutilayotgan sotuvga nisbati|PULM (Pulmatrix) - Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori Pheton (PTHL)|Forvard P/S multiplikatori APM|Forvard P/S multiplikatori Lyra Therapeutics Inc (LYRA)|Narxning prognoz qilingan daromadga nisbati Impact BioMedical Inc IBO|TNF Pharmaceuticals Inc. - Narxning prognoz qilingan daromadga nisbati|YCBD - Narxning prognoz qilingan daromadga nisbati|Kapitalizatsiyaning kutilayotgan sotuvga nisbati PainReform Ltd PRFX|altamiratherapeutics.com (CYTO) - Narxning prognoz qilingan daromadga nisbati|Kelajakdagi narxning daromadga nisbati LIPO (Lipella Pharma)|OPTN (OptiNose, Inc.) - Forvard P/S multiplikatori|procapsgroup.com (PROC) - Kapitalizatsiyaning kutilayotgan sotuvga nisbati|Narxning prognoz qilingan daromadga nisbati Petros Pharmaceuticals, Inc. (PTPI)|QLI (Qilian International Holding Group) - Sotuvga nisbatan forvard narx|Narxning prognoz qilingan daromadga nisbati ACELYRIN, Inc. SLRN|Kapitalizatsiyaning kutilayotgan sotuvga nisbati TFF Pharmaceuticals, Inc (TFFP)
